Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fudanafil
- Development stage
- Phase 1
- Lead developer
- Xuanzhu Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fudanafil is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor developed by Xianzhu Biotechnology, a subsidiary of Sihuan Pharmaceutical. It is currently under clinical investigation for the treatment of pulmonary arterial hypertension (PAH) and erectile dysfunction (ED). By inhibiting the PDE5 enzyme, fudanafil prevents the hydrolysis of cyclic guanosine monophosphate (cGMP), thereby increasing intracellular cGMP levels in smooth muscle cells. This mechanism promotes nitric oxide-mediated vasodilation in the pulmonary vasculature and the corpus cavernosum, which serves to reduce pulmonary vascular resistance and improve erectile function, respectively. Fudanafil is designed to offer a competitive therapeutic profile within the PDE5 inhibitor class, aiming for improved efficacy or safety compared to established agents like sildenafil and tadalafil.
- Other names
- fudanafil
02
Targets
PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on fudanafil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fudanafil.